Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2014-10-21 Regulatory Filings
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Immediate Report
Regulatory Filings
2014-10-21 Hebrew (modern)
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. The key content is the announcement: 'Attached hereto is a report on *Kamada Announces Study in Support of Alpha-1 Antitrypsin for the Treatment of Type-1 Diabetes Published in the Journal of Diabetes Science and Technology*'. Since the document itself is short (1694 chars) and its primary function is to announce the publication of another report (a study/press release), it fits the definition of a Report Publication Announcement (RPA). It is not the full study, nor is it a standard financial report like 10-K or IR.
2014-10-21 English
Annual General Meeting / Special Meeting
Regulatory Filings
2014-10-12 Hebrew (modern)
Annual General Meeting / Special Meeting
Regulatory Filings
2014-10-12 Hebrew (modern)
Annual General Meeting / Special Meeting
Regulatory Filings Classification · 1% confidence The document explicitly mentions that the corporation will hold a 'special meeting' on 13/11/2014. It refers to an 'Attached Proxy Card' and a 'proxy statement' related to this meeting. The content strongly indicates materials being distributed to shareholders in preparation for a general meeting, which aligns with the definition of AGM Information (AGM-R) or Proxy Solicitation & Information Statement (PSI). Since it specifically mentions the proxy card and statement for a meeting, PSI is highly relevant, but AGM-R covers general meeting materials. Given the context of a meeting notice and attached proxy materials, AGM-R (AGM Information) is the most appropriate high-level classification for meeting-related documents, although PSI is also very close. However, the presence of the proxy card and statement strongly points towards shareholder solicitation materials. Let's re-evaluate the definitions: AGM-R is for 'Presentations and materials shared during the Annual General Meeting (AGM)'. PSI is for 'Materials sent to shareholders to provide information and request votes for meetings.' Since this is a notice for a *special* meeting and includes the proxy statement/card, PSI is technically more precise than AGM-R (which often implies the *Annual* meeting). However, in many filing systems, proxy materials for any general meeting fall under the broader AGM/EGM category. Given the explicit mention of 'Proxy Card' and 'proxy statement', PSI is the best fit among the options provided for soliciting votes for a meeting. If PSI was not available, AGM-R would be the next best choice. I will select PSI as it specifically covers proxy solicitation materials.
2014-10-12 English
Annual General Meeting / Special Meeting
Regulatory Filings
2014-10-09 Hebrew (modern)

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.